Bayer: Time for a break

NEUTRAL vs. BUY, Fair Value EUR82 vs. EUR75 (+2%)

News published on April Friday 26, 2013
Share on

Yesterday, Bayer revealed a below-than-consensus first quarter mainly due to a disappointment for the Material Sciences franchise and for mature product sales. Thus we move our estimates on sales and EBITDA for the year to adjust for the “new guidance” of the company, i.e. flat EBITDA vs last year (vs a slight increase). Also we apply a new valuation model for the stock represented by the average between a global DCF valuation, the EVA method and a SOTP method. Thus we achieve a FV of EUR82 vs EUR75 previously. Considering the good performance over the last few months driven by a very impressive R&D result flow and now a lack of significant newsflow in short term, we downgrade the stock to NEUTRAL.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities